# Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Source: https://onco.cc/trials/nct07551362/  
OnCo record `nct07551362` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine and Cyclophosphamide in gastric & gastro-oesophageal junction cancer, run by Beijing Biotech, now recruiting.

## Summary

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer is a phase 1/2 interventional study registered as NCT07551362 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DT-CAR-NK, Fludarabine and Cyclophosphamide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07551362
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Study of Allogeneic Dual-target CLDN18.2/HER2 (ERBB2) CAR-NK Cells After Fludarabine/Cyclophosphamide Lymphodepletion in
- Sponsor: Beijing Biotech
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07551362: https://clinicaltrials.gov/study/NCT07551362

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07551362.json